Although M2-like tumor-associated macrophages (TAMs) have been considered as a vital therapeutic target in cancer therapy due to their role in promoting tumor progression and metastasis, very few compounds have been identified to inhibit M2-like polarization of TAMs. Here, we showed that Imatinib significantly prevented macrophage M2-like polarization induced by IL-13 or IL-4 in vitro, as illustrated by reduced expression of cell surface marker CD206 and M2-like genes, including Arg1, Mgl2, Mrc1, CDH1, and CCL2. Further, the migration of lung cancer cells promoted by the conditioned medium from M2-like macrophages could be restrained by Imatinib. Mechanistically, Imatinib inhibited STAT6 phosphorylation and nuclear translocation, resulting in the macrophage M2-like polarization arrest. Furthermore, Imatinib reduced the number of metastasis of Lewis lung cancer without affecting tumor growth. Both in tumor and lung tissues, the percentage of M2-like macrophages decreased after the administration of Imatinib for one week. Taken together, these data suggest that Imatinib is able to inhibit macrophage M2-like polarization, which plays a vital role in Imatinib suppressed metastasis of Lewis lung cancer.
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A B S T R A C T
Although M2-like tumor-associated macrophages (TAMs) have been considered as a vital therapeutic target in cancer therapy due to their role in promoting tumor progression and metastasis, very few compounds have been identified to inhibit M2-like polarization of TAMs. Here, we showed that Imatinib significantly prevented macrophage M2-like polarization induced by IL-13 or IL-4 in vitro, as illustrated by reduced expression of cell surface marker CD206 and M2-like genes, including Arg1, Mgl2, Mrc1, CDH1, and CCL2. Further, the migration of lung cancer cells promoted by the conditioned medium from M2-like macrophages could be restrained by Imatinib. Mechanistically, Imatinib inhibited STAT6 phosphorylation and nuclear translocation, resulting in the macrophage M2-like polarization arrest. Furthermore, Imatinib reduced the number of metastasis of Lewis lung cancer without affecting tumor growth. Both in tumor and lung tissues, the percentage of M2-like macrophages decreased after the administration of Imatinib for one week. Taken together, these data suggest that Imatinib is able to inhibit macrophage M2-like polarization, which plays a vital role in Imatinib suppressed metastasis of Lewis lung cancer.
Introduction
Compelling clinical and experimental evidence suggests that high infiltration of macrophages in most human cancers is associated with tumor malignancy, poor prognosis and tumor recurrence. Meta-analyses indicate that high density of TAMs, especially M2 subset, corresponds to worse overall survival (OS) in patients with lung cancer, gastric cancer, breast cancer, etc. [1] [2] [3] [4] . TAMs infiltrated in primary tumors or metastatic sites play a crucial role in delivery of tumor cells from the primary site to distant tissues in various murine models [5] [6] [7] [8] . TAMs in the peripheral blood are believed to mediate circulating tumor cells extravasation and facilitate their seeding into distant metastatic sites [9, 10] . Clodronate-liposome-mediated deletion of macrophages suppresses metastasis in many tumor grafted models [11] [12] [13] . Either targeting CCL2 which recruits inflammatory monocytes or targeting CSF-1R which induces macrophage polarization has been proved to be effective for preventing tumor metastasis [5, 7, [14] [15] [16] .
Accumulating evidence suggests that whether macrophages execute tumor-promoting or tumor-suppressing activities depends on their subphenotype which is dynamically switched [17] [18] [19] . Macrophage activation is broadly categorized as classically activated, or M1, and alternatively activated, or M2 in response to different microenvironmental stimuli. M1-like polarization of macrophages are activated by toll-like receptor agonists (e.g., LPS) and Th1 cytokines (e.g., INFγ) with enhancing abilities of phagocytosis, pro-inflammatory cytokines production (e.g., TNFα), and tumor destruction. Alternatively, M2-like polarization of macrophages, which produce secretory factors to promote angiogenesis, matrix remodeling, and tumor progression, is induced by Th2 cytokines, like IL-13 and IL-4 [19, 20] . This M1/M2 concept helps to explain macrophage heterogeneity. To more accurately characterize the complexity of M2-like macrophage activation. Mantovani et al. suggested that macrophages could be further classified into M2a, M2b, M2c, and M2a + M2c types based on the distinct repertoires of chemokines and chemokine receptors [21] . TAMs in malignant tumors tend to resemble alternatively activated macrophages (M2-like), which enhance tumor-associated angiogenesis, promote the ability of tumor migration and invasion, as well as suppress the anti-tumor immune responses [21] [22] [23] .
STAT6, as a transcription factor and signaling molecule, has been proved to play a key role in IL-4 or IL-13 induced M2-like polarization of macrophages [24, 25] . It is reported that IL-4 can bind to either type I receptor or type II receptor, while IL-13 usually binds to the type II receptor [25] . This binding triggers the phosphorylation of the JAKs, which subsequently phosphorylate STAT6. Upon activation, STAT6 dimerize and translocate into the nuclear, where they bind to DNA and initiate the transcription of target genes. In addition, CSF1-CSF1R signaling cascade, PI3K pathway and ERK signaling pathway are also reported to contribute to macrophage M2-like polarization [26, 27] . Blockade of these signaling pathways can suppress tumor growth and metastasis by inhibiting M2-like polarization of macrophages, further suggesting that TAM is a potential target in cancer therapy [14, 15] .
Imatinib is a tyrosine kinase inhibitor and firstly used for Philadelphia chromosome-positive (Ph + ) chronic myelogenous leukemia (CML) [28] [29] [30] . It has also been found that Imatinib has therapeutic effect on several solid tumors. For example, the anti-metastasis function of Imatinib is reported in breast cancer, lung cancer and dermato fibrosarcoma protuberans when it is used alone or combined with other anti-tumor agents [31] [32] [33] [34] [35] . However, controversial results come out that Imatinib increases lung metastasis in breast tumor grafted murine models [36, 37] . The published studies which focused on inhibition of cell proliferation or induction of cell apoptosis, are not able to fully explain of Imatinib in cancer therapy.
Given the vital role of M2-like TAMs in tumor metastasis, we investigated the effect of Imatinib on the polarization of macrophages. In our study, we found that Imatinib suppressed M2-like polarization via the inhibition of STAT6 phosphorylation and subsequent nuclear translocation. Furthermore, the results showed that Imatinib could restrain the metastasis of Lewis lung cancer caused by M2-like macrophages, both in vitro and in vivo. Importantly, Imatinib reduced the M2-like macrophages not only in primary tumor tissues but also at metastatic site. Our study suggested the inhibition of macrophage M2 polarization may contribute to the anti-metastasis activity of Imatinib.
Material and methods
Ethics statement
Investigation has been conducted in accordance with the ethical standards according to the Declaration of Helsinki and the national and international guidelines, and has been approved by the authors' institutional review board.
Materials
Imatinib mesylate was obtained from Selleck Chemicals (Shanghai, China) and its solutions were prepared at the stock concentration of 50 mM (DMSO). Recombinant murine IL-13, IL-4 and M-CSF were purchased from PeproTech (Rocky Hill, NJ). LPS was purchased from Sigma-Aldrich (St. Louis, MO) and IFNγ was purchased from R&D systems (Minneapolis, USA). The primary antibodies against STAT6, CSF1R, p-CSF1R (Y708), CD206 and β-actin were obtained from Santa Cruz Biotechnology (CA, USA); p-STAT6 (Y641), Ym1 and Mrc1 were obtained from Abcam (Cambridge, UK); JAK2 and p-JAK2 (T1007/ 1008) were obtained from Cell Signaling Technology (Cambridge, UK). The antibody against CD68 was obtained from eBioscience (San Diego, CA, USA). PE-conjugated anti-mouse CD206, PE-conjugated anti-mouse CD86 and FITC-conjugated anti-mouse F4/80 were purchased from Biolegend (San Diego, CA, USA 
Bone marrow derived macrophages isolation and differentiation
C57BL/6 (4-6 weeks old) mice were sacrificed and bone marrow were isolated. The bone marrow cells were cultured in DMEM with 10% fetal bovine serum and incubated with M-CSF (50 ng/mL) for three days to acquire BMDMs [38] . Single cell suspensions were prepared from tumor and lung tissues using gentle MACS™ Dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany). The procedure of flow cytometry was performed as previously described [38] with small modification. Single cells were incubated with PE-conjugated CD206, FITC-conjugated F4/80, PE-conjugated CD3, FITC-conjugated CD8 or FITC-conjugated CD4 antibodies. At least 1 × 10
5 cells of each sample should be analyzed. For FoxP3 detection, CD4 + T cells were fixed, permeabilized, and stained with PEconjugated anti-mouse FoxP3 antibody using TF Fix/Perm Buffer (BD Bioscience).
Real-time PCR assay
Total RNA from RAW264.7 cells and BMDMs was isolated using Trizol (Invitrogen, CA, USA), and cDNA was synthesized using TransScript One-Step gDNA Removal and cDNA Synthesis SuperMix (TransGen Biotech, Beijing, China). The real-time PCR assay was performed by SYBR Green Master Mix (Bio-Rad Laboratories, CA, USA). The reaction mixtures were prepared following manufacture's protocol. Relative mRNA level of target genes was normalized with the β-actin of control. Detail information of the primers was showed in Table 1 .
Immunofluorescence of cells
RAW264.7 cells were treated with or without 10 ng/mL IL-13 and/ or 2.5 μM Imatinib for 1 h before harvest. Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20 min at room temperature. Cells then were permeabilized with 0.1% TritonX-100 in PBS for 10 min at 4°C and blocked by 4% bovine serum albumin (BSA) in PBS at 37°C for 30 min. Cells were then incubated with primary antibody against STAT6 overnight at 4°C and Alexa Fluor 488-labeled secondary antibody for 1 h at room temperature in PBS containing 4% BSA. Cells were incubated with DAPI (DOJINDO, Shanghai, China) for 5 min at room temperature and then covered with fluoromount-G (Southern Biotech, USA) for observation.
Tumor models
C57BL/6 (4-6 weeks old) mice were obtained from Beijing Vital LLCs intravenous model: 1 × 10 6 LLC cells (in DMEM) were injected intravenously to each mouse. Imatinib (in PBS) was given orally at 70 mg/kg once a day. Mice were sacrificed 3 days (n = 3 per group), 7 days (n = 3 per group), or 25 days (n = 6 per group) after the injection of tumor cells. For analysis of pulmonary metastasis, lungs of LLCs subcutaneous model were removed, fixed in paraformaldehyde and cut into 3 μm thickness sections every 200 μm throughout the whole lung. Sections were stained with hematoxylin and eosin, and screened histologically. The number of metastatic lung nodes was counted.
Lungs of LLCs intravenous model were removed. Lung tissues were cut into 2 parts at 3th, 7th and 25th day after injection of tumor cells. One was measured by flow cytometry and another was directly embedded in O.C.T. compound and analyzed by immunofluorescence. Metastatic nodes on the surface of lungs of mice 25 days after injection of tumor cells were counted. Lungs were then fixed in paraformaldehyde and analyzed by Immunohistochemistry.
Hematoxylin and eosin (H&E) staining
Lungs were perfused with 4% formaldehyde and then fixed in 4% paraformaldehyde, embedded in paraffin and sectioned at a thickness of 3 μm. All sections were stained with hematoxylin-eosin by an autostainer(ST5010, Leica, Germany)according to standard procedures.
Immunohistochemistry and immunofluorescence of tumors and lungs
Lungs were fixed and sectioned as previous. Antigen retrieval of each sample was achieved with citrate buffer. Sections were incubated with anti-mouse CD206, CD86 or F4/80 antibodies. Later, sections were stained with DAB.
Tumors or lungs were dissected and directly embedded in O.C.T. compound. Sections were fixed with cold 4% paraformaldehyde, immunostained with goat anti-mouse CD206, rabbit anti-mouse CD86, or rat anti-mouse CD68 primary antibodies, and followed by Alexa Fluor 
Conditioned medium preparation
BMDMs were cultured in DMEM with 10% FBS and treated with IL-13 (10 ng/mL) and/or Imatinib (2.5 μM) for 24 h. Then the supernatants were discard and changed into serum-free medium for further 24 h, after which the new supernatants of these cells were obtained as conditioned medium (CM).
Trans-well assay
The migration assay was performed using a Trans-well Boyden Chamber (Costar, Bethesda, MD, USA). LLC cells (5 × 10 4 /well) were seeded into the upper chamber with 200 uL CM, and the same CM (600 μL) was added in the lower chamber. After incubated at 37°C for 12 h, cells were fixed with cold 75% ethyl alcohol for 40 min. The non-migrant cells on the upside of upper chamber were removed by cotton buds. The migrant cells on the bottom of upper chamber were stained with 0.1% crystal violet and then photographed by a microscope. At least three fields of each well were randomly chosen and analyzed by Image-Pro Plus 6.0.
Western blot analysis
Protein was harvested and western blot was performed as previously described [39] . Primary antibodies against STAT6, CSF1R, p-CSF1R (Y708), were used at 1:500 dilution. Primary antibodies against β-actin, p-STAT6 (Y641), JAK2, p-JAK2 (T1007/1008), Ym1 and Mrc1 were used at 1:1000 dilution.
Statistical analyses
All samples were analyzed by at least three independent experiments. Data were analyzed by Student's t-test and are expressed as mean ± SD. Differences were statistically significant when the p value was less than 0.05.
Results
Imatinib inhibited M2-like polarization of macrophages in vitro
RAW264.7 cells were treated with serial concentrations of Imatinib for 72 h and cell survival fraction was assessed by SRB (sulphorhodamine B). Data showed that Imatinib did not affect the proliferation of RAW264.7 cells in the concentrations below 5 μM ( Supplementary  Fig. 1A ). Cell viability assay and apoptosis were analyzed by flow cytometry. As a results, the percentages of apoptotic cells treated with IL-13 (10 ng/mL) and/or Imatinib (5 μM) were less than 20%, which meant IL-13 and Imatinib did not cause apoptosis of RAW264.7 cells (Supplementary Fig. 1B ). Then we explored the impact of Imatinib on macrophage M2-like polarization by flow cytometry. The expression of CD206 was markedly induced by IL-13, which was suppressed by Imatinib in a concentration-dependent manner (Fig. 1A) . Similarly, Imatinib effectively abolished the up-regulation of CD206 induced by IL-4 (10 ng/mL) in RAW264.7 cells. Meanwhile, the expression of CD86 was not affected by IL-4 and/or Imatinib (Fig. 1B) .
We further confirmed the inhibitory effect of Imatinib on the M2-like polarization in BMDMs. As shown in Supplementary Fig. 1C , Imatinib did not cause remarkable growth inhibition of BMDMs. However, IL-13 triggered up-regulation of CD206 was dramatically restrained by Imatinib in a concentration-dependent manner (Fig. 1C) . Convincingly, the up-regulated protein expression of Mrc1 and Ym1 was also diminished by Imatinib ( Supplementary Fig. 1D and E). To further explore the impact of Imatinib on macrophage M2 polarization, the transcription level of M2 genes was studied by quantitative realtime PCR. Significant up-regulation of Arg1, Mgl2, Mrc1, CDH1 and CCL2 were observed when BMDMs were stimulated with IL-13, which was prominently inhibited by Imatinib (Fig. 1D ).
M1-like macrophage polarization was not affected by Imatinib
To further confirm the role of Imatinib in macrophage polarization, we analyzed the effect of Imatinib on M1-like polarization. RAW264.7 cells were treated with LPS (2.5 ng/mL) and IFNγ (0.125 ng/mL) and/ or Imatinib (0.63, 1.25, 2.5 μM) for 48 h and then were assessed by flow cytometry. The data showed that LPS and IFNγ significantly increased the percentage of CD86 positive cells, which were not affected by Imatinib (Fig. 2A) . Similar results were obtained from RAW264.7 cells and BMDMs when treated with Imatinib for various times (Supplementary Fig. 2A-C) . Additionally, quantitative real-time PCR was performed to explore the changes of M1 related genes. Similarly, the upregulation of relative mRNA level of iNOS, TNFα, and CCL5 induced by LPS and IFNγ were not affected by Imatinib both in RAW264.7 cells and BMDMs ( Fig. 2B and Supplementary Fig. 2D ).
Imatinib attenuated the migration-promoting function of M2-like macrophages
To investigate the impact of Imatinib on the interaction between M2 macrophages and tumor cells, trans-well assay was performed to detect the migration ability of LLC cells when cultivated with conditioned medium (CM) from BMDMs. BMDMs were incubated with IL-13 and/or Imatinib for 24 h and the supernatant were replaced with fresh serumfree medium. 24 h later, the supernatant of these cells were collected as conditioned medium (Fig. 3A) . CM from BMDMs treated with IL-13 promoted the migration of LLC cells in 12 h, while CM from BMDM treated with both IL-13 and Imatinib did not has this effect ( Fig. 3B and  C) . Furthermore, cell proliferation and apoptosis of LLC cells were detected respectively after incubated with 4 types of CM for 12 h. There was no significant difference among groups ( Fig. 3D and E) , suggesting that CM did not affect the survival of LLC cells.
In addition, LLC cells were treated directly with IL-13 and/or Imatinib for 12 h, and the migration ability was also detected. No significant difference was observed in the invasion of LLC cells ( Supplementary Fig. 3A and B) . Besides, IL-13 and Imatinib did not affect the proliferation and apoptosis of LLC cells ( Supplementary  Fig. 3C and D) .
Imatinib inhibited M2-like polarization of macrophages via prevention of STAT6 phosphorylation and nuclear translocation
Given that STAT6 plays a key role in IL-13 or IL-4 induced macrophage M2-like polarization [24, 25] , we assessed whether STAT6 is involved in Imatinib inhibited M2 polarization. IL-13 markedly triggered the phosphorylation of STAT6 in 30 min, and reached a peak in 1 h, which was significantly restrained by Imatinib (Fig. 4A and B) . Furthermore, the translocation of STAT6 into nuclear promoted by IL-13 was suppressed by Imatinib (Fig. 4C) . Because STAT6 is classical activated by JAK2, we analyzed JAK2 phosphorylation upon IL-13 or IL-4 stimulation and/or Imatinib treatment. We found that IL-13 or IL-4 stimulated JAK2 phosphorylation was not affected by Imatinib, which suggested that Imatinib inhibited the phosphorylation of STAT6 through JAK2-independent pathway (Supplementary Fig. 4A ).
It has been reported that CSF1 (M-CSF)/CSF1R-mediated signaling is vital for the differentiation and proliferation of the monocyte-macrophage linage [40] . Dewar AL demonstrated that Imatinib targets CSF1R to affect the growth and development of monocytes/ macrophages [41] . Therefore, we investigated whether CSF1R participated in Imatinib-inhibited M2-like polarization of macrophages. Our data showed that the phosphorylation of CSF1R was not affected by IL-13 stimulation and/or Imatinib treatment while CSF1R phosphorylation up-regulated by M-CSF was reversed by Imatinib ( Supplementary  Fig. 4B ).
Imatinib blocked pulmonary metastasis in vivo by targeting M2-like macrophages
We further evaluate the impact of Imatinib on metastasis in both LLC subcutaneous model and intravenous model. Imatinib was dissolved in PBS and given orally at 70 mg/kg every day, while mice in the control group were treated with vehicle. There was no significant difference in the increase of body weight between two groups (Fig. 5A and  F) . Also, no significant difference in the subcutaneous tumor growth was observed (Fig. 5B) . However, the number of metastatic nodes in lung tissues was prominently reduced by Imatinib treatment (Fig. 5C  and D) . Intriguingly, the ratio of mice which had metastatic nodes in Imatinib group was noticeably lower than control group (Fig. 5E) .
Similar results were obtained in the LLC intravenous model. Metastatic nodes on the surface of lungs were considerably reduced by Imatinib (Fig. 5G and H) . These results suggested that Imatinib blocked pulmonary metastasis in either LLC subcutaneous model or LLC intravenous model. Imatinib suppressed macrophage M2-like polarization in primary tumors (Fig. 6A) .
To evaluate the impact of Imatinib on metastatic site, we detected the M2-like TAMs in lung tissues at the 3rd day, 7th day of LLC intravenous model. The percentage of F4/80 + CD206 + cells and CD68 + CD206 + cells were assessed by flow cytometry and immunofluorescence assay. The data showed that there was no significant difference between two groups at the 3rd day ( Fig. 6B and D) . Whereas, in Imatinib treated group, the percentage of F4/80 + CD206 + cells and CD68 + CD206 + cells were decreased at the 7th day ( Fig. 6C and E) .
Furthermore, we studied the impact of Imatinib on TAMs around the metastatic nodes at the 25th day and found that Imatinib significantly reduced CD206 + TAMs at the metastatic nodes without impact on macrophages infiltration (Fig. 6F) . These results suggested that Imatinib inhibited M2-like polarization at the metastatic site. Additionally, we also assessed the effect of Imatinib on M1-like macrophages polarization in vivo. The data showed that Imatinib did not affect M1-like macrophage polarization in primary tumors ( Supplementary Fig. 5A ). Besides, there was no significant difference in the CD86 + TAMs at the metastatic nodes between two groups ( Supplementary Fig. 5B ). These data suggested Imatinib did not affect between two groups at the 3th, 5th and 25th day ( Supplementary  Fig. 6A-C) . Similarly, in primary tumor tissues of LLC subcutaneous model, no significant difference was observed at the 21st day ( Supplementary Fig. 6D ). These results suggested that Imatinib did not affect the T cells-meditated immune response in LLC mouse models.
Discussion
Imatinib mesylate, the first tyrosine kinase inhibitor approved in clinic use, has showed remarkable activity against Ph + hematological malignancies and metastatic solid tumors, especially GIST [42] . Imatinib is widely used in KIT + GIST, due to its inhibition of c-kit, a kind of tyrosine kinase enzymes [43] . It has been illustrated that Imatinib inhibited bone metastasis of breast cancer by the blockade of CSF1R signals [44] . Several studies showed that Imatinib has a therapeutic effect on colorectal metastasis and proliferation of tumor cells via abrogating PDGFR signaling pathway [36, 37, 45] . Whereas, opposing effect of Imatinib as a PDGFR inhibitor is also reported. It may attribute to its impact on PDGF-β signaling in pericytes from PDGF-BB-lowproducing or PDGF-BB-negative tumors [36] . The mechanism of antimetastasis of Imatinib remains unclear. Furthermore, there are also studies showed that the anti-tumor activity of Imatinib partially depended on immune cells like T cells [46, 47] . As TAMs are the most abundant immune cells in tumor microenvironment which contribute to tumor malignancy [48] , we investigated the effect of Imatinib on polarization of TAMs and tumor metastasis. M2-like polarization of macrophages is driven by IL-4 and IL-13 secreted by immune cells like T H 2 cells. By the employment of IL-13 or IL-4 induced M2 polarization models, we found that Imatinib efficiently suppressed the expression of prototypical M2 marker CD206 and M2 genes. Furthermore, we also confirmed that the conditioned medium of M2-like macrophages induced by IL-13 promoted the migration of LLC cells, as the previous study reported [38] . Meanwhile, the migration of LLC cells was attenuated when incubated with the conditioned medium of BMDMs treated with Imatinib and IL-13. However, there was no significant difference between the migration of LLC cells treated directly with IL-13 and/or Imatinib. Therefore, Imatinib can diminish tumors migration through the inhibition of M2 macrophage polarization induced by IL-13 or IL-4.
It is demonstrated that Imatinib targets macrophage colony-stimulating factor receptor (CSF1R) which is tightly related to the proliferation and differentiation of monocytes and macrophages [41] . We analyzed the role of CSF1R in the blockage of M2 polarization and found M-CSF induced CSF1R phosphorylation could be inhibited by Imatinib. Given that M-CSF may also be present in primary tumors and/ or metastatic sites, this reverting effects would also contribute to the inhibitory effect of Imatinib. Nevertheless, IL-13 did not affect the phosphorylation level of CSF1R, which suggested that CSF1R might not participate in Imatinib inhibited M2 polarization. It is well-known that STAT6 has a dual role as transcription factor and signaling molecular, which is closely connected to IL-13/IL-4 signaling, and plays a vital role in M2 polarization of macrophage [49] . Here we found that IL-13-induced STAT6 phosphorylation and nuclear translocation was diminished by Imatinib in macrophages. Previous study illustrated that IL-13 binds to the heterodimerization of IL-13Rα1 and IL-4Rα which are the critical components for tyrosine phosphorylation of STAT6 [25] .
Actually, the receptor system of IL-13/IL-4 do not have intrinsic kinase activity and their initial signaling dependent on JAKs [24] . In specific, IL-13/IL-4 binds to their receptors, subsequently activates and phosphorylates JAK2. The activated JAK2 then phosphorylates three tyrosine residues on receptors, which provide docking sites for STAT6. Thus, we analyzed the phosphorylation of JAK2 to confirm the modulate the premetastasis niche to promote tumor extravasation, survival and persistent growth [19, 50] . Due to the multiple functional roles of TAMs, Qian and Pollard suggested that specialized subpopulations of macrophages may represent important new therapeutic targets and could be classified into six subtypes: angiogenic, immunosuppressive, invasive, metastasis-associated, perivascular, and activated macrophages [19] . Iriki T et al. suggested that TAMs are involved in small cell lung cancer progression via STAT3 activation and TAM −derived IL-6, which indicates that TAMs can be a target for lung cancer therapy [51] . It is also reported that TAMs enhance metastasis in lung carcinoma by promoting tumor cell proliferation and migration [52] . In our study, we found that Imatinib significantly inhibited pulmonary metastases in two models without significant inhibitory effect in tumor growth. Furthermore, our data also showed Imatinib suppressed M2-like polarization in the primary tumor of LLC subcutaneous model. To test whether Imatinib affect circulating tumor cell seeding at metastatic sites, we injected LLC cells intravenously into mice and detected the percentage of M2-like TAMs. We found Imatinib not only decreased the percentage of M2-like TAMs in primary tumor tissues, but also suppressed M2-like polarization of TAM at metastatic sites. However, it is reported that Imatinib enhanced TAM M2 polarization in GIST. In this study, TAM in GIST were reported to display an M1-like phenotype and function at baseline, which is very different from most cancers [43, 53] . Our study indicated that Imatinib may be effective in the anti-metastatic strategy for cancers in which TAMs show M2-like function and play a vital role in tumor malignancy. Interestingly, the study of D. Keskin et al. showed that Imatinib, which targets pericytes via PDGFRβ, reduced pericyte coverage and resulted in an increase in lung metastasis [37] . Whereas, in our study, we found that Imatinib prevented lung metastasis by targeting macrophages. Both mechanisms could exist, and the final outcome could be a balance between these two mechanisms depending on the model used. Since Imatinib could inhibit the M2 polarization of macrophages, the model which has more invasion of macrophage would benefit from Imatinib. No matter in which situation, the combination with angiopoietin 2 inhibitors would help to avoid Imatinib induced vascular leakage. There are several clinical trials focused on the anti-tumor effect of Imatinib mesylate in lung cancer patients. Most results indicated no apparent improvement in outcomes when administrated with Imatinib alone (NCT00052949, NCT00156286, NCT00248482). In our study, we found that Imatinib could inhibit M2-like polarization, which doesn't mean that patients would benefit from Imatinib alone. Although large numbers of evidence indicate an important role of macrophage in cancer progression, targeting macrophages is considered as adjuvant strategy for cancer therapy. In this regard, Imatinib should be combined with other agents in lung cancer therapy. Currently, the combination of Imatinib with traditional chemotherapy has been explored in several clinic trials (NCT00045604, NCT01083589, NCT00052494, et al). However, the trials were terminated because of an increase in toxicity (NCT00323362, NCT02127372). Alternatively, new treatment options that combined Imatinib with targeting agents, such as TKIs and a monoclonal antibodies still worth clinical trial.
Conclusions
In summary, our findings indicate Imatinib inhibits macrophage M2-like polarization both in vitro and in vivo which contributes to its anti-metastatic function in lung cancer. Furthermore, we identify STAT6 plays a vital role in the effect of Imatinib on M2-like polarization of macrophages. Besides, we find that Imatinib inhibits the percentage of M2-like TAMs not only in primary tumor but also at the metastatic site, which means Imatinib may interfere the multiple steps of lung metastasis. Our study provides the experimental proof for the application of agents targeting M2-like macrophages in anti-metastatic therapy. Although the single in vivo model of primary and metastatic lung cancer is analyzed, we can suggest the new potential application of Imatinib in anti-lung metastasis therapeutic strategy, and the further exploration of Imatinib on more metastatic models would be performed. 
